Episodes (Page 3)
✨
Consumers use AI for self-care but lack trust.
Chris Rebholz
Christian Danelund
✨
European biotech leaders discuss competitiveness challenges.
✨
Oncology biosimilars expand access and manage healthcare costs.
Colin Farquharson
Martin Lachs
✨
ElevateBio bets on multiple gene editing modalities and delivery systems.
Amy Pooler
✨
Medicines for Europe legal and annual conferences reviewed.
Anabel Costa-Ferreira
Dave Wallace
✨
US FDA clarifies journal articles are not official guidance.
✨
Eisai discusses broadening Leqembi's use with subcutaneous version.
Michael Irizarry
✨
Biopharma M&A deals over $1bn are closing faster.
Bruce Leuchter
✨
Health literacy is often misunderstood by companies.
Trevor Gore
✨
FDA may solidify presumption to release complete response letters.
✨
Tonix Pharmaceuticals is developing TNX-4800, a monoclonal antibody for Lyme disease prevention.
Seth Lederman
✨
Dr. Reddy's Chairman Satish Reddy discusses strategic use of generic Revlimid gains.
✨
China's drug regulator finalized data protection measures for registered drugs.
✨
The obesity drug market is rapidly growing, led by Eli Lilly's tirzepatide.
✨
China deal-making dominated discussions at the BIO convention.
✨
IPA Europe's Rosanna Pecere discusses the socioeconomic value of probiotics.
Rosanna Pecere
✨
China deal-making was a hot topic at the BIO convention.
✨
FDA issued new guidance on the one-trial efficacy standard for drug approval.
✨
Clinical operations should be a board-level strategic function, not a cost center.
Claire Riches
✨
The PRECEDE-Azenta partnership aims to improve early detection of pancreatic cancer.
Margaret Caspler